Synchron, which develops non-surgical brain-computer interface (BCI) technology, has raised a US$200 million in a series d financing round.
The funding will accelerate commercialisation of the company’s first-generation Stentrode BCI platform, the company says, while advancing development of a frontier next-generation interface.
The platform is the world’s first endovascular brain-computer interface, designed to translate brain activity into digital commands without open-brain surgery.
Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices. Stentrode BCIs have been placed in 10 patients with paralysis to date, across clinical trials in the U.S. and Australia.
Synchron was the first BCI company to integrate Apple’s BCI-human interface device (BCI-HID), having co-developed a Bluetooth-based iOS protocol that connects brain activity directly to Apple devices using Switch Control, including iPad, iPhone and Vision Pro – no touch, voice, or eye-tracking required.
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Tom Oxley, CEO and founder, Synchron.
“This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
An expanding cognitive AI division in New York City will train models that learn from brain data to decode thought in real time.
In parallel, its new San Diego engineering hub has been established to build the world’s most advanced brain interface.
The funding round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS.
New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. The financing brings Synchron’s total funding to US$345m.
“Synchron is building the first truly scalable, minimally invasive brain-computer interface that can be deployed in everyday healthcare,” said Campbell Murray, co-founder and managing partner at Double Point Ventures.
“Its fusion of neurovascular access, breakthrough device engineering, and adaptive AI marks a fundamental step toward restoring digital agency to people with paralysis.”
